Table 1:

Rodent models of neurodegenerative disease that shown benefit from therapeutic inhibition of PARP-1/2.

Disease	Model	Inhibitors	Treatment	Sacrifice	Effect of PARP-1/2 inhibitor	ref.
AD	rat - Injection of Aβ(1–42) into hippocampal C3 region	niacin	daily i.p.i. for 7 d	7 d post Aβ(1–42) injection	reduced lipid peroxidation & ROS	[120]
HD	mouse – transgenic for exon 1 of Htt with 150 CAG repeats driven by human Htt promoter		daily i.p.i. from 28 d onward	/	improved lifespan & motor deficits	[121]
Ischemic stroke	mouse –MCAO & ACAO	INH2BP	i.p.i. 2 hr before occlusion.	25 hr/75 hr post MCAO & ACAO	inhibition of PARP-1/2 activity & reduced infarct size	[122]
	mouse – MCAO	PJ34	i.p.i. 1 hr and 2hr before occlusion	24 hr & 72 hr post MCAO	reduced iNOS expression & reduced infarct size	[123]
	mouse – MCAO	DPQ	i.p.i. 1 hr and 2hr before occlusion	24 hr & 72 hr post MCAO	reduced infarct size	[123]
	mouse – MCAO	DPQ	i.p.i. 2 hr before and 2 hr after occlusion	24 hr post MCAO	reduced infarct size	[124]
PD	mouse – i.p.i. of MPTP 4 times at 1hr intervals	benzamide	i.p.i. 30 min before and 90 min after first MPTP injection	5 d post MPTP injection	mitigated loss of tyrosine hydroxylase	[125]
	mouse – unilateral injection of α-syn PFF into striatum	ABT-888	Mice were fed ABT-888	3 & 6 mo post injection of α-syn PFF	improved motor deficits (3 mo post α-syn PFF injection) & mitigated loss of DA neurons (6 mo post α-syn PFF injection)	[45]

Abbreviations: AD: Alzheimer’s disease; HD: Huntington’s disease; PD: Parkinson’s disease; MCAO: middle cerebral artery occlusion; ACAO anterior cerebral artery occlusion; i.p.i.: intraperitoneal injection; PFF: preformed fibril; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; iNOS: induced nitric oxide synthase; INH₂BP: 5-iodo-6-amino-1,2-benzopyrone; DPQ: 4-dihydro-5-[4(1-piperidinl)butoxyl]-1-(2H)-isoquinolinone; mo: month; DA: dopaminergic neurons.